Xilio Therapeutics (NASDAQ:XLO) Stock Price Down 0.3% – What’s Next?

Xilio Therapeutics, Inc. (NASDAQ:XLO) traded down 0.3% during trading on Wednesday . The company traded as low as $9.05 and last traded at $9.28. Approximately 65,011 shares traded hands during trading, an increase of 57% from the average daily volume of 41,338 shares. The stock had previously closed at $9.31.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Weiss Ratings lowered shares of Xilio Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, July 1st. Wall Street Zen lowered shares of Xilio Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Xilio Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.00.

Xilio Therapeutics Stock Down 0.3%

The firm has a 50 day moving average of $8.42 and a 200 day moving average of $8.41. The firm has a market cap of $61.06 million, a PE ratio of -2.61 and a beta of -0.14.

Xilio Therapeutics (NASDAQ:XLO) last released its earnings results on Tuesday, May 12th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.08. The business had revenue of $12.65 million during the quarter, compared to the consensus estimate of $8.52 million. Xilio Therapeutics had a negative return on equity of 151.42% and a negative net margin of 58.52%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Jane Street Group LLC purchased a new stake in Xilio Therapeutics in the 4th quarter worth about $27,000. Velan Capital Investment Management LP purchased a new stake in Xilio Therapeutics during the fourth quarter valued at about $109,000. State Street Corp lifted its holdings in Xilio Therapeutics by 13.7% during the fourth quarter. State Street Corp now owns 186,390 shares of the company’s stock valued at $119,000 after purchasing an additional 22,500 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Xilio Therapeutics by 68.3% during the fourth quarter. Renaissance Technologies LLC now owns 344,416 shares of the company’s stock valued at $220,000 after purchasing an additional 139,716 shares during the last quarter. Finally, Squarepoint Ops LLC boosted its position in Xilio Therapeutics by 39.6% during the third quarter. Squarepoint Ops LLC now owns 328,794 shares of the company’s stock worth $277,000 after purchasing an additional 93,338 shares during the period. Institutional investors own 54.29% of the company’s stock.

About Xilio Therapeutics

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.